Financials in USD. Standardized financial statements.
A compact view of how CannaPharmaRX, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.36M | $820,137 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +66.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $3.45M | $3.75M | $65,561 | $294,934 | $14,364 | $128,505 | $129,035 | $0 | $0 | $0 |
| Gross Profit? | -$2.08M | -$2.94M | -$65,561 | -$295,000 | -$14,364 | -$129,000 | -$129,000 | $0 | $0 | $0 |
| Gross Margin? | -153.1% | -357.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $1.26M | $671,330 | $1.58M | $5.21M | $2.62M | $4.51M | $2.85M | $532,772 | $6,633 | $1.00M |
| Operating Income? | -$3.35M | -$3.61M | -$1.58M | -$5.21M | -$2.99M | -$14.49M | -$15.98M | -$954,000 | -$6,633 | -$1.00M |
| EBITDA? | -$8.68M | -$7.64M | -$1.45M | -$4.91M | -$2.61M | -$17.47M | -$2.85M | -$954,000 | -$6,633 | -$992,860 |
| Income Before Tax | -$11.13M | -$9.91M | $3.69M | -$8.53M | -$8.83M | -$19.89M | -$20.45M | -$3.09M | -$6,633 | -$1.00M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $423 |
| Net Income? | -$11.13M | -$9.91M | $3.69M | -$8.53M | -$8.83M | -$19.89M | -$20.45M | -$3.09M | -$6,633 | -$1.00M |
| EPS? | $-0.02 | $-0.02 | $0.01 | $-0.04 | $-0.12 | $-0.49 | $-0.66 | $-0.17 | $-0.00 | $-0.06 |
| Diluted EPS? | $-0.02 | $-0.02 | $0.01 | $-0.04 | $-0.12 | $-0.49 | $-0.66 | $-0.17 | $-0.00 | $-0.06 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality